-
226 patients with metastatic breast cancer have been enrolled in the AIPAC study
-
Combination of eftilagimod alpha, an antigen presenting cell (APC) activator, administered in combination with chemotherapy is designed to boost the T-Cell immune responses against tumours
-
Read-out of progression-free survival (PFS) primary endpoint expected to occur in Q1 of calendar year 2020
SYDNEY, AUSTRALIA – June 25, 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces that it has completed patient enrolment of the Phase IIb Active
Immunotherapy PAClitaxel (AIPAC) clinical trial in HER2-negative/ Hormone Receptor positive (HR+) metastatic breast cancer (MBC).
For further information please download the attached PDF:
Download this document
